Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NVNO

enVVeno Medical Corporation

Apr 30 • 04:00PM ET

5.30

Dollar change +0.08
Percentage change 1.53	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.02	Insider Own	0.38%	Shs Outstand	13.32M	Perf Week	-3.64%
Market Cap	70.60M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	-14.14%	Shs Float	13.27M	Perf Month	0.57%
Income	-23.52M	PEG	-	EPS next Q	-0.40	Inst Own	35.35%	Short Float	6.38%	Perf Quarter	17.00%
Sales	0.00M	P/S	-	EPS this Y	20.90%	Inst Trans	0.88%	Short Ratio	6.37	Perf Half Y	3.92%
Book/sh	3.47	P/B	1.53	EPS next Y	52.14%	ROA	-52.09%	Short Interest	0.85M	Perf Year	30.70%
Cash/sh	3.48	P/C	1.52	EPS next 5Y	-	ROE	-55.38%	52W Range	2.51 - 6.97	Perf YTD	3.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.51%	ROI	-49.75%	52W High	-23.96%	Beta	1.11
Dividend TTM	-	Quick Ratio	34.23	Sales past 5Y	-36.65%	Gross Margin	-	52W Low	111.16%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	34.23	EPS Y/Y TTM	12.35%	Oper. Margin	0.00%	RSI (14)	52.61	Volatility	8.83% 5.95%
Employees	31	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	20.40
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	34.98%	Payout	-	Rel Volume	0.11	Prev Close	5.22
Sales Surprise	-	EPS Surprise	6.25%	Sales Q/Q	-	Earnings	Oct 26 BMO	Avg Volume	133.04K	Price	5.30
SMA20	4.86%	SMA50	-4.51%	SMA200	8.54%	Trades		Volume	14,792	Change	1.53%

Apr-24-24 06:15AM	Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium (ACCESSWIRE) -5.09%
Apr-16-24 09:00AM	New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 (ACCESSWIRE)
Apr-09-24 08:45AM	enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer (ACCESSWIRE)
Mar-15-24 09:00AM	enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity (ACCESSWIRE)
Mar-06-24 08:40AM	Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting (ACCESSWIRE) -7.02%
04:15PM	Loading…
Feb-29-24 04:15PM	enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (ACCESSWIRE) -6.32%
Feb-20-24 08:30AM	Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024 (ACCESSWIRE) +9.96%
Dec-14-23 11:30AM	enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium (ACCESSWIRE)
Nov-16-23 08:45AM	enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium (ACCESSWIRE) -5.92%
Oct-26-23 08:05AM	enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-12-23 09:00AM	enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference (ACCESSWIRE)
Oct-06-23 08:57AM	enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial (ACCESSWIRE) -13.72%
08:56AM	enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve (ACCESSWIRE)
08:55AM	enVVeno Medical Announces Private Placement of $28 Million (ACCESSWIRE)
04:45PM	Loading…
Jul-31-23 04:45PM	enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-14-23 08:05AM	enVVeno Medical to Host Virtual KOL Event on July 18, 2023 (ACCESSWIRE)
Jul-05-23 08:05AM	enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events (ACCESSWIRE) +5.56%
May-01-23 08:00AM	enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-02-23 05:15PM	enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-08-23 09:00AM	enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference (ACCESSWIRE)
Jan-18-23 08:05AM	enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer (ACCESSWIRE)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Nov-17-22 12:00PM	Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues (ACCESSWIRE)
Nov-07-22 08:45AM	enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study (ACCESSWIRE)
Oct-27-22 04:05PM	enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Sep-22-22 08:05AM	enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference (ACCESSWIRE) -6.62%
Sep-21-22 04:01PM	enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency (ACCESSWIRE) -8.97%
Sep-19-22 08:05AM	enVVeno Medical to Host Conference Call and Webcast on September 21, 2022 (ACCESSWIRE)
Sep-12-22 07:00AM	enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE) +6.54%
08:05AM	Loading…
Aug-16-22 08:05AM	enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations (ACCESSWIRE)
Aug-03-22 04:45PM	enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-08-22 08:05AM	enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein (ACCESSWIRE) +12.67%
May-02-22 08:00AM	enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-25-22 03:47PM	Do Institutions Own McDonald's Corporation (NYSE:MCD) Shares? (Simply Wall St.)
Apr-21-22 04:32PM	Statement from McDonald's Corporation in Response to Mr. Icahn's Media Outreach (PR Newswire) +6.36%
03:11PM	Carl Icahn takes on McDonald's over treatment of pigs (American City Business Journals)
11:39AM	Heres how Wolfgang Pucks restaurants have responded to inflation (Yahoo Finance)
08:00AM	Carl C. Icahn Files Definitive Proxy Statement and Issues Open Letter to Shareholders of McDonald's Corporation (Business Wire)
Apr-20-22 02:28PM	McDonald's launches ad campaign to thank its workers (American City Business Journals)
Apr-11-22 08:05AM	enVVeno Medical Announces New U.S. VenoValve(R) Patent (ACCESSWIRE) -5.59%
Mar-28-22 07:05AM	enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update (ACCESSWIRE) +26.67%
Mar-24-22 12:53PM	Inflation hasn't stopped Olive Garden diners from ordering endless breadsticks, salads (Yahoo Finance)
Mar-22-22 12:43PM	Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation (Simply Wall St.)
Mar-09-22 08:35AM	One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery (ACCESSWIRE)
Feb-25-22 08:05AM	Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum (ACCESSWIRE) +10.95%
Feb-16-22 09:05AM	enVVeno Medical Announces ISO 13485 Certification (ACCESSWIRE)
Feb-03-22 05:38PM	Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ... (GuruFocus.com)
Jan-20-22 08:30AM	enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference (ACCESSWIRE)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Nov-16-21 08:20AM	enVVeno Medical to Present at the Virtual Investor Roundtable Event (ACCESSWIRE)
Nov-11-21 08:05AM	enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th (ACCESSWIRE)
Oct-22-21 09:00AM	enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial (ACCESSWIRE)
Oct-01-21 07:02AM	enVVeno Medical Corporation Successfully Completes Rebranding (ACCESSWIRE)

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alavi Hamed	Chief Technology Officer	Mar 13 '24	Option Exercise	3.59	8,334	29,919	8,334	Mar 15 08:00 PM
Alavi Hamed	Chief Technology Officer	Mar 13 '24	Sale	6.22	8,334	51,837	0	Mar 15 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVNO

enVVeno Medical Corporation

Upgrade your FINVIZ experience